Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer - Australia
doi 10.7150/jca.37670
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

Outcome of Eribulin as a Late Treatment Line for Thai Metastatic Breast Cancer Patients

OncoTargets and Therapy
OncologyPharmacology
2018English

Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2010English

Assessing the Tolerability and Efficacy of First-Line Chemotherapy in Elderly Patients With Metastatic HER2−ve Breast Cancer

ecancermedicalscience
Cancer ResearchOncology
2019English

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2016English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer

Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
2011English

Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy